LifeSci Communications Fierce Pharma Asia—Takeda's Anima mRNA translation pact, China digital health incubator; Daiichi's COVID-19 vaccine

Takeda penned a potentially billion-dollar deal with Anima Biotech to work on mRNA translation modulators for neurological diseases. The Japanese pharma als

World's First Inhalable COVID-19 Vaccine Approved in China - COVID-19 - mobile.

Daiichi Sankyo applies for approval of mRNA COVID vaccine The Asahi Shimbun: Breaking News, Japan News and Analysis

AbbVie to Develop mRNA Modulators Using Anima Biotech Platform

Sponsor Detail Template – Chinese American Biopharmaceutical Society

Daiichi Sankyo to supply omicron XBB.1.5-adapted COVID-19 vaccine in Japan

Anima Biotech - mRNA Lightning Platform

PharmaCompass – Grow Your Pharma Business Digitally

BioSpectrum Asia Jan 2023 - Flip eBook Pages 1-50

Japan's Daiichi Sankyo to seek OK for omicron booster by April 2024 - Nikkei Asia

Walvax Biotechnology Co Ltd

Anima Biotech - Company info. interviews, news

PharmaCompass – Grow Your Pharma Business Digitally